Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marius Nap

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2013
PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinomaRachel L G M Blom, Inge R Steenbakkers, Guido Lammering, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2011
FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancerJeroen Buijsen, Jørgen van den Bogaard, Marco H M Janssen, et al.
Experimental Cell Research|June 15, 2004
Keratin 8/18 breakdown and reorganization during apoptosisBert Schutte, Mieke Henfling, Wendy Kölgen, et al.
BMC Cancer|August 19, 2016
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsRuben T H M Larue, Lien Van De Voorde, Maaike Berbée, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
European Journal of Nuclear Medicine and Molecular Imaging|June 15, 2013
PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinomaRachel L G M Blom, Inge R Steenbakkers, Guido Lammering, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2011
FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancerJeroen Buijsen, Jørgen van den Bogaard, Marco H M Janssen, et al.
Experimental Cell Research|June 15, 2004
Keratin 8/18 breakdown and reorganization during apoptosisBert Schutte, Mieke Henfling, Wendy Kölgen, et al.
BMC Cancer|August 19, 2016
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsRuben T H M Larue, Lien Van De Voorde, Maaike Berbée, et al.
Pageof 3